Radiopharmaceutical Administered activity Number of cycles Time interval between cycles (weeks) 90Y-DOTATATE/90Y-DOTATOC 3.7 GBq (100 mCi)/m2 2 10–12 90Y-DOTATATE/90Y-DOTATOC (another protocol) 2.78–4.44 GBq (75–120 mCi) 2–4 10–12 177Lu-DOTATATE/177Lu DOTATOC 5.55–7.4…
Organ involved Specific tumor (prevalence by 40 years) Clinical presentation MEN1 Parathyroid disease (95 %) Diffuse hyperplasia Symptoms related to hypercalcemia or hypercalciuria Adenoma, multiple NETs PNETs (30–80 %)…
© Springer-Verlag Berlin Heidelberg 2015Suayib Yalcin and Kjell Öberg (eds.)Neuroendocrine Tumours10.1007/978-3-662-45215-8_33 33. Societies and Guidelines for Neuroendocrine Tumors Kjell Öberg1 (1) Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden Kjell Öberg Email: kjell.oberg@medsci.uu.se 33.1 Historical Background…
11. Therasse P, Arback SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer (EORTC),…
© Springer-Verlag Berlin Heidelberg 2015Suayib Yalcin and Kjell Öberg (eds.)Neuroendocrine Tumours10.1007/978-3-662-45215-8_30 30. Somatostatin Analogs and Interferon in the Treatment of Neuroendocrine Tumors Jonathan Strosberg1 (1) Neuroendocrine Tumor Program, H. Lee Moffitt Cancer Center and Research Institute,…
Tumor type Oversecretion of main substances Clinical syndromes All NENs CgA Carcinoid Serotonin Carcinoid syndrome Insulinoma Insulin, C peptide or proinsulin Hypoglycemia and neuroglycopenia Gastrinoma Gastrin Zollinger-Ellison syndrome (ZES) Glucagonoma…
Symptom Frequency (%) Flushing 85 Telangiectasia 25 Cyanosis 18 Pellagra 2–25 Diarrhea 75–80 Abdominal cramp 75 Bronchospasm 20 Valvular lesions 50 Right heart 40 Left heart 13 Asthenia <5 Neuropsychiatric…
Frequency (%) Features of MTC Associated diseases Sporadic MTC 70 Unifocal MEN-2A 20 Autosomal dominant Multifocal, bilateral Pheochromocytoma Primary parathyroid hyperplasia Cutaneous lichen planus amyloidosis (rare) Hirschsprung disease (rare)…
Stage Macfarlane [43] Lee et al. [45] I T1 (<5 cm) N0M0 T1 (<5 cm) N0M0 II T2 (>5 cm) N0M0 T2 (>5 cm) N0M0 III T3 (local invasion without…
ENETS TNM UICC/AJCC/WHO 2010 TNM T classification Limited to the pancreas, <2 cm Limited to the pancreas, ≤2 cm in greatest dimension Limited to the pancreas, 2–4 cm Limited to…
